We named the firm after the thing our clients are actually buying: a route into the Gulf that someone has already walked.
Hodion Advisory is an independent, principal-led consultancy focused on one thing: pharmaceutical market access in Saudi Arabia and the Gulf. Hodion began in 2025 as an independent research practice, built on a decade of operating inside the region's market — competing in NUPCO tenders and supporting institutional access across the Kingdom's largest hospital systems, with particular depth in oncology, transplant, and critical care.
Most Gulf market intelligence available to international companies is produced from outside the region — syndicated reports, desk research, and generalist networks. It describes the rules. What it misses is how decisions are actually made: which pathway a regulator will realistically apply, where the pricing methodology leaves room, how the evaluation criteria weight a close bid.
That gap is why Hodion exists. We are small by design — a principal-led practice, not a pyramid — and we take engagements where in-market knowledge changes the outcome. We exist to close the gap between good therapies and the patients who need them.
Every Hodion engagement is delivered by the principal — no juniors, no handoffs. Our principal is a serving commercial professional in the Gulf pharmaceutical sector. That is why this page carries no name: a deliberate position, not an omission. The same discretion that keeps our principal's current role separate from this firm is the discretion that will keep your product, your pricing, and your entry plan private when you work with us.
The principal's identity and background are shared in confidence in the first conversation. What we can tell you publicly is below.
The principal, in specificsIf the pathway is blocked, we say so before you spend. An early "no" from us is worth more than a late one from the regulator.
We don't sell 200-page landscapes. We answer the decision in front of you with exactly the evidence it needs.
Gulf access runs through a small number of institutions. Understanding how each one decides is the entire craft.
We work under strict confidentiality, avoid conflicts across competing mandates, and keep client identities private by default.
Our sharpest expertise sits in high-complexity institutional categories — where access is decided by specialist centers, tender committees, and formulary boards rather than retail dynamics:
Hodion does not represent, lobby, or negotiate with the SFDA, NUPCO, or any Gulf health authority or government purchasing body on a client's behalf. What we sell is analysis: how the pricing methodology works, how the tender calendar runs, how a formulary committee weighs a submission, and what the published award history shows — reconstructed from public rules, published records, and professional experience of operating within the system.
We do not hold competing mandates in the same product category at the same time, and we are glad to complete a client's compliance questionnaire, sign an anti-bribery certification, or go through a third-party risk assessment before an engagement begins.
If a request would require influence rather than analysis, we decline it — and we say why.
Start with one conversation. We'll give you an honest read on whether — and how — the region works for your product.
Get in touch